Introduction
Recently, several investigators reported controversial results regarding the influence of NOD2 gene polymorphisms on the outcome of allogeneic transplant. [1] [2] [3] [4] [5] [6] [7] [8] [9] Some groups suggested that NOD2 gene variants SNP8 (R702W, rs2066844), SNP12 (G908R, rs2066845) and SNP13 (1007fs, rs2066847) might increase the incidence of severe acute GVHD, whereas others associated presence of the gene variant with increased risk of relapse, bronchiolitis obliterans with organizing pneumonia or treatment-related mortality. 1, 3, 7, 9 Other investigators did not find an influence of NOD2 gene variants on GVHD, treatment-related mortality or bronchiolitis obliterans with organizing pneumonia. 4, 6, 8 However, the varying results might in part be explained by substantial differences between the patient populations studied, that is, patients transplanted with T-cell-depleted grafts, 2, 7, 9 in contrast to patients transplanted with unmanipulated grafts. 1, [3] [4] [5] Other variables include the underlying diseases at the time of transplant as well as the type of donors (unrelated or sibling) used. We therefore aimed to study the role of NOD2 gene variants and other gene variants (TLR9:T1237C, rs5743836; T1486C, rs187084; IL23R:A1142G and rs11209026) in a more homogenous group of patients with AML transplanted from HLA-identical sibling donors after myeloablative conditioning therapy.
Besides NOD2 gene variants, other gene variants have also been found to influence transplant outcomes. We and others reported that patients transplanted from donors with a gene variant of the IL23 receptor (A1142G) have a markedly reduced risk for developing severe acute GVHD grade II-IV. 6 ,10 Furthermore, we reported recently that a gene polymorphism of Toll-like receptor 9 T1486C has a favorable influence on the incidence of treatment-related mortality with improved transplant outcomes compared with patients carrying the wild type of this gene.
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Toll-like receptors and NOD2 are receptors of the innate immune system that recognize and bind to invading microbial pathogens through several so-called pathogenassociated molecular patterns. 12, 13 TLR9 is located intracellularly and senses single-stranded DNA from microbial pathogens containing unmethylated CpG motifs, thereby inducing an adaptive immune response characterized by production of inflammatory cytokines and IFNs. TLR9 expression has been reported in B and T cells including CD4 þ T cells and regulatory T cells, APCs, neutrophils, monocytes and epithelial cells. However, on binding to its specific ligands, TLR9 activates and regulates nuclear factor-kB, several kinases and immune-responsive genes by recruiting adaptor molecules to their intracellular signaling domain.
IL23 is a member of the IL12 family that has a critical role in promoting inflammatory responses mediated by type 1 T-helper cells. IL23 and IL12 share some molecule structures. The IL12 cytokine consists of covalently linked p40 and p35 subunits, and IL23 is composed of the IL12 p40 chain associated with a p19 subunit. Functional IL23 receptor is a heterodimer composed of a shared IL12 receptor b 1 (IL12Rb1) and an IL12Rb2-related molecule called IL23R that contains the coding variant 1142G4A we evaluated here. Both cytokines induce proliferation and IFN-g production by T-cells, which are also mediators of acute GVHD. 17, 18 Patients and methods
Patients
The entire study population consisted of 142 transplant recipients and their HLA-identical sibling donors who were transplanted at the University Hospital of Essen between January 1999 and January 2009 after receiving a myeloablative conditioning therapy. All patients received unmanipulated grafts containing T cells. Gene polymorphism analyses were performed without the knowledge of the study end points of the analyzed patients. Pretransplant histocompatibility testing of donors and patients generally consisted of low-resolution HLA-A, -B, -C and highresolution HLA-DRB1, DQB1 DNA-based typing according to standard methods. 19 Inclusion criteria were the availability of pretransplant blood samples and the willingness of the patients to participate in the study. Conditioning regimens have been previously published 20 Patients characteristics are given in Table 1 . All patients and donors gave their written informed consent according to protocols approved by institutional review board on medical ethics at the University Hospital of Essen.
Isolation of genomic DNA DNA was prepared from PBMCs obtained from the donor and patient before the transplant using the Magna Pure device from Roche diagnostics (Mannheim, Germany).
Genotyping of SNP
Genotyping for SNP8 (R702W, rs2066844), SNP12 (G908R, rs2066845) and SNP13 (1007fs, rs2066847) of the NOD2/CARD15 gene was performed with a Taqman protocol, as published earlier. 1 Genotyping for TLR9 (T1486C, rs187084), TLR9 (T1237C, rs5743836) and IL23R (A1142G, protein Arg381Gln, rs11209026) was analyzed by a Lightcycler protocol using hybridization probes and primers as published before. 10, 11 Call rate for genotyping for SNP8, SNP12 and SNP13 was 99.3% each and that for TLR9 and IL23R was 100%. PCR primers were synthesized by MWG Biotech (Ebersberg, Germany). The fluorescence-labeled sensor and anchor hybridization probes for the Lightcycler protocol and Taqman probes were purchased from TIB MOLBIOL (Berlin, Germany). Sensor probes cover the SNP and exhibit a different melting temperature dependent on binding to the wild-type or variant allele. Anchor probes were designed to display a significantly higher melting temperature compared with the corresponding sensor probes. PCR and subsequent melting curve analysis were performed using the Lightcycler device and software. Control samples confirmed by sequencing were included in each run.
Statistical analysis
Acute and chronic GVHD were diagnosed and graded according to standard criteria. 21, 22 Death in remission was defined as any death occurring before the recurrence of the underlying disease. The cumulative rates of incidence of acute GVHD, chronic GVHD and death in remission, and OS were calculated with the Kaplan-Meier method. 23 Differences between time-to-event distribution functions were compared by a log-rank test (Mantel-Haenszel). A stepwise proportional hazards general linear model analysis was used to evaluate interactions of different covariates on the analytical end point of acute GVHD and OS. Covariates in proportional hazards general linear model analyses stratified according to severe acute GVHD (only for the end point OS); age (p40 or 440 years); gender constellation (male patient with female donor or other); gene variants of TLR9, NOD2 and IL23R; grafttype (PBSC or BM) and disease stage (advanced vs first CR) were analyzed. Conditional risk ratios (RR) and their 95% confidence intervals (95% CI) were derived from proportional hazards general linear model analyses after adjustment for significant covariates in the model. The demographic characteristics of the groups were compared by means of descriptive methods, and significant differences were identified by Fisher's exact test. Statistical analysis was performed using SPSS software version 13.0 (SPSS Inc., Chicago, IL, USA). Only patients surviving more than 30 days were included in the analysis of acute GVHD. A minimum of 100 days of follow-up was required for patients to be included in the analysis of chronic GVHD.
Results
Frequencies of gene polymorphisms NOD2 SNP8, SNP12 or SNP13 were found in 20.5% of patients and 17.5% of donors. The homozygous TLR9 gene variant CC at 1486 was found in 19.8% of patients and 20.6% of donors. The heterozygous IL23R gene variant was found in 10.3% of patients and 11.6% of donors. All frequencies were in the expected field as published earlier. 1, 11, 12 Acute GHVD Patients with NOD2 gene variants had an increased incidence of acute GVHD grade I-IV (67.8 vs 88%; Po0.035) and severe acute GVHD grade III-IV (28 vs 12.8%; P ¼ 0.065). In contrast, patients transplanted with donors with IL23R gene variant had a decreased incidence of acute GVHD grade I-IV (64.7 vs 71.8%; NS). Moreover, none of the patients transplanted from donors with IL23R gene variant developed a severe acute GVHD grade III-IV (0 vs 18.4%; Po0.048).
No influence on the occurrence of acute GVHD grade I-IV or III-IV was found in patients with TLR9 gene variants. The results are shown in Figure 1 .
Estimate for relapse at 5 years after transplant There was no association found between incidence of relapse and NOD2 or IL23R gene variants in this study (Figure 2 ). Patients with CC gene variant of TLR9 had an improved estimated relapse rate after transplant of 21 vs 45% (P ¼ 0.045).
Estimate for death in remission at 5 years after transplant No significant difference in the estimated rate of death in remission at 5 years after transplant was found in patients with NOD2 gene variants compared with patients with the wild-type NOD2 after transplant (6.3 vs 24.8%; P ¼ 0.6), as well as in patients transplanted from donors with IL23R gene variant (12.5 vs 23.1%; P ¼ 0.39). However, patients transplanted with TLR9 gene variant showed an improved estimated rate of death in remission, which did not reach statistical significance (7.8 vs 23.1%; P ¼ 0.07). The results are shown in Figure 3 . Multivariate analysis for OS and acute GVHD grade II-IV According to this multivariate analysis, the gene variant of NOD2 increased the risk for the occurrence of acute GVHD grade II-IV (RR 3.7652; 95% CI 1.60-7.91; Po0.002) besides patient age over 40 years (RR 2.704; 95% CI 1.06-6.89; Po0.037) and stage (RR 2.96; 95% CI 1.35-6.48; Po0.007), whereas the gene variant of IL23R at donor side showed no significant influence for acute GVHD. OS of patients was not influenced by any of the gene variants in this multivariate analysis.
Discussion
In this study, we evaluated the influence of three different gene variants on the clinical outcome in a homogenous group of patients with AML after myeloablative, non-Tcell-depleted transplant. In our study, only the gene variant TLR9 with the homozygous C allele at position 1486 influenced the outcome of transplant, whereas the occurrence of NOD2 gene variant or IL23R gene did not significantly affect OS. TLR9 1486 SNP improved the outcome of transplant by reducing the transplant-associated mortality rate and further by reducing the rate of relapse similarly as reported recently. 11 Consequently, the estimated OS improves to 70.2 compared with 44.8% in patients with the gene variant TLR9. Interestingly, the reduced relapse rate found here for patients with TLR9 GVHD1-4 GVHD 3-4 GVHD1-4 GVHD 3-4 GVHD 1-4 GVHD 3-4 Figure 1 The incidence of acute GVHD grade I-IV and severe acute GVHD grade III-IV. Acute GVHD grade I-IV (P ¼ 0.035) and severe acute GVHD grade III-IV (P ¼ 0.065) occurred more often in patients with NOD2 gene variants. However, no severe GVHD grade III-IV occurred in patients transplanted from donors with gene variant of IL23R (P ¼ 0.048). No differences in the incidence of acute GVHD were seen for patients with homozygous CC gene variants of TLR9 at 1486 compared with patients with the wild-type TLR9 or TC gene variant. gene variant after transplant was not associated with an increased occurrence of acute or chronic GVHD. However, patients after transplant are jeopardized by opportunistic infections and, therefore, often confronted with TLR9-activating CpG-rich DNA sequences (oligonucleotides (ODNs)) from microbial invaders. In addition, non-CpG containing DNA sequences originating from apoptotic cells after conditioning regimen or after GVHD reactions could frequently induce the activation of TLR9. Therefore, TLR9 is often involved in a variety of immune responses arising at multiple occasions throughout the whole post transplant period, comparable with its involvement in the progression of autoimmune disease such as systemic lupus erythematosus, which can be regarded as a different kind of overwhelming immune response. 14, [24] [25] [26] [27] [28] [29] Some reports suggest that CpG-rich ODNs as TLR9 ligands are able to induce overwhelming immune responses such as sepsis or systemic inflammatory response syndrome, thus endangering patients after transplant. 25 Studies using C57BL/6 knockout mice showed that TLR9 À/À recipients of grafts had an improved survival and less GVHD after transplant compared with TLR9 þ / þ mice. The observed reduced mortality and morbidity in TLR9À/À mice were associated with reduced stimulatory activity of TLR9À/À spleen APCs after conditioning and reduced proliferation of allogeneic donor T cells. 24 Indeed, the gene variant with homozygous C alleles at 1486 is associated with reduced TLR9 gene expression in patients after transplant, as reported earlier. Further, TLR9 is reported to influence activation and proliferation of CD4 þ T cells, CD4 þ CD25 þ T-regulatory cells and B cells. 14, 25 Moreover, we found that the cellular immune reconstitution of CD4 þ T-helper cells and CD3 þ CD8 þ cytotoxic T cells after transplant were slower in patients with CC alleles at 1486 as compared with patients with the wild-type gene at 1486. Another reason for a moderate immune response in patients with CC alleles of 1486 might be caused by the role of TLR9 ligands on the activity of CD þ CD24 þ T-regulatory cells. Reportedly, ligands of TLR9 partially abrogate the suppressive activity mediated by regulatory CD4 þ CD25 þ T cells.
14 Reduced TLR9 expression, as found in the genetic variant of À1486, causes less suppressive activity on regulatory CD4 þ CD25 þ T cells, which has an important role, for example, in the immune response of transplanted patients to infections.
It remains unclear how TLR9 gene variant might exert a favorable influence on relapse rates after transplant or whether this association found here is only a coincidence. However, Blazar et al. described that CpG-rich ODN possess anti-leukemic features in ALL and AML. 30, 31 They
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Relapse rate TLR9 but not NOD2 polymorphism influence outcome in AML AH Elmaagacli et al postulated that the anti-leukemic effect of CpG-rich ODNs depended on natural killer cells rather than T or B cells in transplant recipients using T-cell-depleted transplant models. They also found that donor lymphocyte infusions combined with CpG-rich ODNs unfold a synergistic effect in mice experiments. 31 Here again we found that patients with a gene variant of NOD2 influenced the incidence and severity of acute GVHD without impacting the outcome of transplant as shown earlier. Up to date, many studies about NOD2 gene variants and transplant exist with contrary results. Mayor et al. 9 found a negative impact of NOD2 on relapse rates in patients with acute leukemia after T-cell-depleted transplant, whereas other study groups suggest an influence on the transplant mortality of NOD2 gene. We and others could not confirm any influence of NOD2 gene variant on relapse or transplant mortality, however, in a non-T-celldepleted transplant setting. It is often argued that T-cell depletion and bacterial gut decontamination in study patients are reasons for the contradicting results observed between different study groups. Indeed, systemic gut decontamination using antibiotics in patients undergoing transplantation reduces the incidence and severity of acute GVHD after transplant. 32 Reducing the bacterial load in the gut with antibiotics also reduces the number of bacterial components as natural ligands of NOD2, which might explain very well an association of NOD2 gene variants with acute GVHD, 1 but its role on relapse rate without affecting the incidence and severity of acute GVHD, as reported, remains unclear. Prospective studies about the role of these gene variants in an independent cohort in the transplant setting are necessary to answer these questions.
In this study, we could further confirm our previously reported finding that a heterozygous gene variant of IL23R on the donor side protects patients from severe acute GVHD grade III-IV. None of the studied patients transplanted from a donor with the IL23R gene variant suffered from severe acute GVHD. These important findings were recently confirmed by another study group investigating transplanted children for this gene variant. 6 Our findings about NOD2 and IL23R gene variants in the transplant setting go along with reports about the same gene variants influencing the incidence of inflammatory bowel disease, underlining the fact that inflammatory bowel disease and acute GVHD share similar immune pathways. [32] [33] [34] A better understanding of the immune modulating effects of NOD2 and IL23R variants on GVHD could lead to future therapeutic strategies in donor selection, prevention and treatment of GVHD. 
